CIK 0001631574
- Large accelerated filer
Wave Life Sciences, Inc.
Sign in to watch- Ticker
- WVE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 617-949-2900
- Business address
- 733 CONCORD AVENUE, CAMBRIDGE, MA, 02138
- Former names
- Wave Life Sciences Ltd., Wave Life Sciences LTD., WAVE Life Sciences Ltd., Wave Life Sciences Pte Ltd
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 45 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-09 | Moran Kyle Chief Financial Officer | Sale | −3,588 | $13.45 | $48K | 134,385 |
| 2026-02-05 | Moran Kyle Chief Financial Officer | Grant or award | +45,625 | 137,973 | ||
| 2026-02-05 | Moran Kyle Chief Financial Officer | Grant or award · Share Option (right to buy) | +273,750 | 273,750 | ||
| 2025-12-09 | Moran Kyle Chief Financial Officer | Exercise or conversion 10b5-1 | +36,000 | $8.17 | $294K | 125,218 |
| 2025-12-09 | Moran Kyle Chief Financial Officer | Sale 10b5-1 | −36 | $20.25 | $729 | 89,218 |
| 2025-12-09 | Moran Kyle Chief Financial Officer | Exercise or conversion 10b5-1 | +50,000 | $10.48 | $524K | 139,218 |
| 2025-12-09 | Moran Kyle Chief Financial Officer | Sale 10b5-1 | −50,000 | $20.03 | $1.0M | 90,365 |
| 2025-12-09 | Moran Kyle Chief Financial Officer | Grant or award · Share Option (right to buy) 10b5-1 | −36,000 | 0 | ||
| 2025-12-09 | Moran Kyle Chief Financial Officer | Grant or award · Share Option (right to buy) 10b5-1 | −50,000 | 0 | ||
| 2025-12-08 | Moran Kyle Chief Financial Officer | Exercise or conversion 10b5-1 | +60,000 | $2.83 | $170K | 149,218 |
| 2025-12-08 | Moran Kyle Chief Financial Officer | Sale 10b5-1 | −60,000 | $13.20 | $792K | 89,218 |
| 2025-12-08 | Moran Kyle Chief Financial Officer | Exercise or conversion 10b5-1 | +100,000 | $3.14 | $314K | 189,218 |
| 2025-12-08 | Moran Kyle Chief Financial Officer | Sale 10b5-1 | −50,000 | $15.00 | $750K | 139,218 |
| 2025-12-08 | Moran Kyle Chief Financial Officer | Sale 10b5-1 | −50,000 | $13.20 | $660K | 89,218 |
| 2025-12-08 | Moran Kyle Chief Financial Officer | Exercise or conversion 10b5-1 | +50,000 | $4.75 | $238K | 139,218 |
| 2025-12-08 | Moran Kyle Chief Financial Officer | Sale 10b5-1 | −50,000 | $18.00 | $900K | 89,218 |
| 2025-12-08 | Moran Kyle Chief Financial Officer | Grant or award · Share Option (right to buy) 10b5-1 | −60,000 | 0 | ||
| 2025-12-08 | Moran Kyle Chief Financial Officer | Grant or award · Share Option (right to buy) 10b5-1 | −100,000 | 75,000 | ||
| 2025-12-08 | Moran Kyle Chief Financial Officer | Grant or award · Share Option (right to buy) 10b5-1 | −50,000 | 222,700 | ||
| 2025-02-04 | Moran Kyle Chief Financial Officer | Grant or award | +42,000 | 89,218 |
Page 1 of 2 · 39 trades